Advancing Immunotherapy for All Cancers
January 12, 2017
Crohn’s Ileal Disease Patients at Higher Risk of Relapse After Surgery
January 12, 2017
Show all

Phase 2 Multiple Sclerosis Study Fully Enrolled, Results Now Due in Fall

A new study looks at an antibody that could help remyelination in multiple sclerosis.

GeNeuro recently announced that it has finished enrolling multiple sclerosis (MS) patients in the CHANGE-MS Phase 2b  study — several months ahead of schedule. The company now expects to report topline results in mid- to late autumn rather than at year’s end.

“Completing enrollment in CHANGE-MS several months sooner than previously anticipated is a significant achievement for our GNbAC1 development program and, most importantly, accelerates the timeline to potentially provide MS patients with a new and effective therapeutic option,” GeNeuro’s CEO, Jesús Martin-Garcia, said in a news release.

The CHANGE-MS (NCT02782858) study is evaluating the effect of GNbAC1 on 260 patients with relapsing-remitting multiple sclerosis (RRMS). Patients were enrolled at multiple clinical sites across Europe.

Its goal is to evaluate whether GNbAC1 can reduce RRMS patients’ active brain lesions — assessed through magnetic resonance imaging (MRI) — at six months and one year after treatment, compared to placebo.

Read full article: Phase 2 Multiple Sclerosis Study Fully Enrolled, Results Now Due in Fall

Read Full Article: Phase 2 Multiple Sclerosis Study Fully Enrolled, Results Now Due in Fall

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.